Spots Global Cancer Trial Database for Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

Official Title: Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Adenocarcinomas

Study ID: NCT04669951

Conditions

Esophagus Cancer, Adenocarcinoma

Interventions

uPAR immunohistochemistry

Study Description

Brief Summary: The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.

Detailed Description: * Sections of the tumor tissue will be HE stained. * Sections of the tumor tissue will be stained with an uPAR antibody for immunohistochemistry. * Immunohistochemical staining against cytokeratin which colors cancer cells will be made to assist the observer in the evaluation of uPAR microexpression pattern. * A semiqualitative scale corresponding to the level of uPAR expression will be made. * Quantitative polymerase chain reaction will be used to validate the immunohistochemistry uPAR expression pattern. * An electronic scoring system (digital pathology) will be trained to access the expression of uPAR in both tumor- and normal tissue.